BR112021023632A2 - Métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratório - Google Patents
Métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratórioInfo
- Publication number
- BR112021023632A2 BR112021023632A2 BR112021023632A BR112021023632A BR112021023632A2 BR 112021023632 A2 BR112021023632 A2 BR 112021023632A2 BR 112021023632 A BR112021023632 A BR 112021023632A BR 112021023632 A BR112021023632 A BR 112021023632A BR 112021023632 A2 BR112021023632 A2 BR 112021023632A2
- Authority
- BR
- Brazil
- Prior art keywords
- nitric oxide
- respiratory tract
- optionally
- compositions
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
Abstract
métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratório. a presente invenção refere-se à combinação, kit ou composição, compreendendo: (i) um ou mais sal de nitrito; (ii) uma fonte de prótons compreendendo um ou mais ácidos selecionados a partir de ácidos carboxílicos orgânicos e ácidos redutores não carboxílicos orgânicos; e (iii) um ou mais poliol orgânico. na reação de um ou mais sal de nitrito com a fonte de prótons na presença de um ou mais poliol orgânico, a combinação, kit ou composição fornece produtos de reação que incluem óxido nítrico, opcionalmente outros óxidos de nitrogênio e/ou opcionalmente precursores dos mesmos e que são úteis no tratamento de vários distúrbios através da distribuição da combinação ou composição ou óxido nítrico, opcionalmente outros óxidos de nitrogênio e/ou opcionalmente precursores dos mesmos a um indivíduo através do trato respiratório.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1907971.4A GB201907971D0 (en) | 2019-06-04 | 2019-06-04 | Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract |
GB201915277A GB201915277D0 (en) | 2019-10-22 | 2019-10-22 | Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract |
GBGB2005979.6A GB202005979D0 (en) | 2020-04-23 | 2020-04-23 | Methods and compositions for generating nitric oxide and uses therof to deliver nitric oxide via the respiratory tract |
PCT/GB2020/051329 WO2020245574A1 (en) | 2019-06-04 | 2020-06-02 | Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021023632A2 true BR112021023632A2 (pt) | 2022-04-19 |
Family
ID=71092559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021023632A BR112021023632A2 (pt) | 2019-06-04 | 2020-06-02 | Métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratório |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220257642A1 (pt) |
EP (1) | EP3980032A1 (pt) |
JP (1) | JP2023510662A (pt) |
CN (1) | CN114126629B (pt) |
AU (1) | AU2020286987A1 (pt) |
BR (1) | BR112021023632A2 (pt) |
CA (1) | CA3142109A1 (pt) |
GB (1) | GB2599818B (pt) |
WO (1) | WO2020245574A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10517817B2 (en) | 2013-05-09 | 2019-12-31 | Syk Technologies, Llc | Deep topical systemic nitric oxide therapy apparatus and method |
JP6513667B2 (ja) | 2013-08-08 | 2019-05-15 | ノヴァン,インコーポレイテッド | 局所用組成物およびそれを使用する方法 |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
WO2021188651A1 (en) | 2020-03-19 | 2021-09-23 | Friedman Joel M | Novel approach to sustained production and delivery of nitric oxide and s-nitrosothiols |
BR112022021454A2 (pt) * | 2020-04-23 | 2023-01-31 | Thirty Respiratory Ltd | Óxido nítrico ou composições liberadoras de óxido nítrico para uso no tratamento de sars-cov e sars-cov-2 |
GB2610721B (en) * | 2020-04-23 | 2024-07-31 | Thirty Respiratory Ltd | Compositions for treating and combatting tuberculosis |
US12059493B2 (en) | 2020-11-09 | 2024-08-13 | Albert Einstein College Of Medicine | Transdermal delivery formulations |
EP4240365A4 (en) | 2020-11-09 | 2024-07-10 | Albert Einstein College Of Medicine | FORMULATIONS FOR TRANSDERMAL ADMINISTRATION |
US20220243065A1 (en) * | 2021-01-29 | 2022-08-04 | Joel Mendelsberg | Filament for 3-d printing of chewable dog toys and treats |
GB202101543D0 (en) | 2021-02-04 | 2021-03-24 | Thirty Respiratory Ltd | Vaping e-liquid composition and the use thereof |
US11786712B2 (en) | 2021-08-30 | 2023-10-17 | Albert Einstein College Of Medicine | Nitric oxide-releasing device |
GB202302117D0 (en) * | 2023-02-14 | 2023-03-29 | Thirty Respiratory Ltd | Compositions, kits and combinations |
GB202302118D0 (en) * | 2023-02-14 | 2023-03-29 | Thirty Therapeutics Ltd | Compositions, kits and combinations |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3826255A (en) | 1972-06-22 | 1974-07-30 | Hudson Oxygen Therapy Sales Co | Intermittent positive pressure breathing manifold |
YU41046B (en) | 1974-08-22 | 1986-10-31 | Schering Ag | Medicine inholating device |
US4130639A (en) | 1977-09-28 | 1978-12-19 | Ethicon, Inc. | Absorbable pharmaceutical compositions based on isomorphic copolyoxalates |
US4268460A (en) | 1977-12-12 | 1981-05-19 | Warner-Lambert Company | Nebulizer |
US4253468A (en) | 1978-08-14 | 1981-03-03 | Steven Lehmbeck | Nebulizer attachment |
US4263907A (en) | 1979-05-14 | 1981-04-28 | Lindsey Joseph W | Respirator nebulizer |
US4510929A (en) | 1982-04-30 | 1985-04-16 | Bordoni Maurice E | Disposable radioactive aerosol inhalation apparatus |
US4649911A (en) | 1983-09-08 | 1987-03-17 | Baylor College Of Medicine | Small particle aerosol generator for treatment of respiratory disease including the lungs |
US4624251A (en) | 1984-09-13 | 1986-11-25 | Riker Laboratories, Inc. | Apparatus for administering a nebulized substance |
NZ241579A (en) | 1991-03-25 | 1994-04-27 | Becton Dickinson Co | Antimicrobial formulations for treating the skin |
US5164740A (en) | 1991-04-24 | 1992-11-17 | Yehuda Ivri | High frequency printing mechanism |
EP0540775B1 (de) | 1991-11-07 | 1997-07-23 | PAUL RITZAU PARI-WERK GmbH | Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie |
US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5709202A (en) | 1993-05-21 | 1998-01-20 | Aradigm Corporation | Intrapulmonary delivery of aerosolized formulations |
WO1995009605A1 (en) | 1993-10-06 | 1995-04-13 | Henkel Corporation | Improving phenolic disinfectant cleaning compositions with alkylpolyglucoside surfactants |
US6034133A (en) | 1993-11-05 | 2000-03-07 | The University Of Virginia Patents Foundation | Use of a virucidal hand lotion to prevent the spread of rhinovirus colds |
BR9507099A (pt) | 1994-02-21 | 1997-09-16 | Aberden University | Forma de dosagem método de esterilização composição esterilizante e suplemento alimentar animal compreendendo nitrito acidificado como um agente anti-microbiano |
GB9804469D0 (en) | 1998-03-02 | 1998-04-29 | Univ Aberdeen | Antiviral composition |
US5681802A (en) | 1994-06-01 | 1997-10-28 | Lever Brothers Company, Division Of Conopco, Inc. | Mild antimicrobial liquid cleansing formulations comprising buffering compound or compounds as potentiator of antimicrobial effectiveness |
US5635462A (en) | 1994-07-08 | 1997-06-03 | Gojo Industries, Inc. | Antimicrobial cleansing compositions |
US5776430A (en) | 1994-11-01 | 1998-07-07 | Calgon Vestal, Inc. | Topical antimicrobial cleanser containing chlorhexidine gluconate and alcohol |
US5648101A (en) * | 1994-11-14 | 1997-07-15 | Tawashi; Rashad | Drug delivery of nitric oxide |
US5702754A (en) | 1995-02-22 | 1997-12-30 | Meadox Medicals, Inc. | Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings |
AU4990696A (en) | 1995-02-24 | 1996-09-11 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
ZA962455B (en) | 1995-03-31 | 1996-10-02 | B Eugene Guthery | Fast acting and persistent topical antiseptic |
US5586550A (en) | 1995-08-31 | 1996-12-24 | Fluid Propulsion Technologies, Inc. | Apparatus and methods for the delivery of therapeutic liquids to the respiratory system |
US5758637A (en) | 1995-08-31 | 1998-06-02 | Aerogen, Inc. | Liquid dispensing apparatus and methods |
US5823179A (en) | 1996-02-13 | 1998-10-20 | 1263152 Ontario Inc. | Nebulizer apparatus and method |
US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
AU726543B2 (en) | 1996-07-10 | 2000-11-09 | S.C. Johnson & Son, Inc. | Triclosan skin wash with enhanced efficacy |
US5906202A (en) | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
US6349719B2 (en) | 1997-02-24 | 2002-02-26 | Aradigm Corporation | Formulation and devices for monitoring the efficacy of the delivery of aerosols |
US6258368B1 (en) | 1997-06-04 | 2001-07-10 | The Procter & Gamble Company | Antimicrobial wipes |
US5855564A (en) | 1997-08-20 | 1999-01-05 | Aradigm Corporation | Aerosol extrusion mechanism |
WO1999017754A1 (en) | 1997-10-08 | 1999-04-15 | Sepracor Inc. | Dosage form for aerosol administration |
DE1129741T1 (de) | 1997-11-19 | 2002-02-21 | Microflow Engineering S.A., Neuenburg/Neuchatel | Sprühvorrichtung für einen Inhalator |
US6192876B1 (en) | 1997-12-12 | 2001-02-27 | Astra Aktiebolag | Inhalation apparatus and method |
US6258371B1 (en) | 1998-04-03 | 2001-07-10 | Medtronic Inc | Method for making biocompatible medical article |
US6103275A (en) | 1998-06-10 | 2000-08-15 | Nitric Oxide Solutions | Systems and methods for topical treatment with nitric oxide |
DE69912793T2 (de) | 1998-07-31 | 2004-09-30 | First Water Ltd., Marlborough | Bioadhäsive Zusammensetzungen und Biomedizinische Elektroden diese enthaltend |
GB2343122B (en) | 1998-10-26 | 2003-01-08 | Medic Aid Ltd | Improvements in and relating to nebulisers |
US6070575A (en) | 1998-11-16 | 2000-06-06 | Aradigm Corporation | Aerosol-forming porous membrane with certain pore structure |
US6584971B1 (en) | 1999-01-04 | 2003-07-01 | Medic-Aid Limited | Drug delivery apparatus |
GB9905425D0 (en) | 1999-03-09 | 1999-05-05 | Queen Mary & Westfield College | Pharmaceutical composition |
JP2000355667A (ja) | 1999-04-14 | 2000-12-26 | Seiko Epson Corp | カラーインクジェット記録用水系顔料インクセット、カラーインクジェット記録方法、及びカラーインクジェット記録物 |
US6338443B1 (en) | 1999-06-18 | 2002-01-15 | Mercury Enterprises, Inc. | High efficiency medical nebulizer |
US6107261A (en) | 1999-06-23 | 2000-08-22 | The Dial Corporation | Compositions containing a high percent saturation concentration of antibacterial agent |
DE60114393T2 (de) | 2000-04-11 | 2006-04-27 | Trudell Medical International, London | Aerosolspender mit einer möglichkeit für positiven ausatemdruck |
GB0021317D0 (en) | 2000-08-30 | 2000-10-18 | Queen Mary & Westfield College | Transdermal pharmaceutical delivery composition |
GB0022084D0 (en) * | 2000-09-08 | 2000-10-25 | Univ Aberdeen | Treatment of multiply antibiotic-resistant organisms |
US6601581B1 (en) | 2000-11-01 | 2003-08-05 | Advanced Medical Applications, Inc. | Method and device for ultrasound drug delivery |
GB0119011D0 (en) | 2001-08-03 | 2001-09-26 | Univ Aberdeen | Treatment of nail infections |
US7135189B2 (en) | 2001-08-23 | 2006-11-14 | Boston Scientific Scimed, Inc. | Compositions and techniques for localized therapy |
GB0125222D0 (en) | 2001-10-19 | 2001-12-12 | Barts & London Nhs Trust | Composition for the treatment of microbial infections |
US7066356B2 (en) | 2002-08-15 | 2006-06-27 | Ecolab Inc. | Foam soap dispenser for push operation |
CA2555552A1 (en) | 2004-02-09 | 2005-09-09 | Noxilizer, Inc. | Nitric oxide-releasing molecules |
US7838532B2 (en) | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
EP1917047B1 (en) | 2005-07-14 | 2019-09-04 | First Water Limited | Treatment of chronic ulcerous skin lesions |
CN101028229B (zh) | 2006-03-02 | 2012-09-05 | 北京富丽华德生物医药科技有限公司 | 基于一氧化氮的新型化妆品 |
CN101062050A (zh) | 2006-04-29 | 2007-10-31 | 北京尼奥克斯生物科技有限公司 | 一种基于一氧化氮的新型生发产品及其制备方法 |
EP2040542A2 (en) | 2006-05-30 | 2009-04-01 | The Dial Corporation | Compositions having a high antiviral effeicacy |
WO2008110872A2 (en) | 2006-06-23 | 2008-09-18 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
GB0700908D0 (en) | 2007-01-17 | 2007-02-28 | First Water Ltd | Inhibition of proteases, particularly in the treatment of chronic ulcerous skin lesions |
GB0700911D0 (en) | 2007-01-17 | 2007-02-28 | First Water Ltd | Treatment of inflammation and the complement and kinin cascades in a patient, particularly in chronic ulcerous skin lesions |
GB0715556D0 (en) | 2007-08-09 | 2007-09-19 | Insense Ltd | Improvements relating to skin dressings |
US9278157B2 (en) * | 2007-08-09 | 2016-03-08 | Insense Limited | Nitric oxide-generating skin dressings |
WO2009086470A2 (en) | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide - donating compounds and uses thereof |
US8568793B2 (en) | 2009-02-11 | 2013-10-29 | Hope Medical Enterprises, Inc. | Sodium nitrite-containing pharmaceutical compositions |
WO2011155887A1 (en) * | 2010-06-07 | 2011-12-15 | Topical Pharma Ab | Kit for the treatment of onychomycosis by nitric oxide |
AU2012296358B2 (en) * | 2011-08-17 | 2016-04-21 | Board Of Regents, The University Of Texas System | Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system |
US20130200109A1 (en) | 2012-02-06 | 2013-08-08 | Frank Yang | Foaming soap dispensers and methods |
CN103690490B (zh) | 2012-08-23 | 2017-11-17 | 尼奥克斯(文莱)控股有限公司 | 基于微囊化化学试剂延时产生一氧化氮的系统和方法 |
US10517817B2 (en) | 2013-05-09 | 2019-12-31 | Syk Technologies, Llc | Deep topical systemic nitric oxide therapy apparatus and method |
GB201309092D0 (en) * | 2013-05-20 | 2013-07-03 | Edixomed Ltd | Transdermal delivery system |
GB201309091D0 (en) | 2013-05-20 | 2013-07-03 | Edixomed Ltd | Dressing system |
ES2964826T3 (es) | 2014-03-14 | 2024-04-09 | Sanotize Res And Developmemt Corp | Composiciones y métodos para tratar enfermedades o trastornos usando soluciones de liberación de óxido nítrico de liberación extendida |
ITUB20154719A1 (it) * | 2015-10-21 | 2017-04-21 | Glano Tech Ltd | Formulazione per il rilascio di ossido nitrico |
DK3407900T3 (da) | 2016-01-27 | 2024-04-02 | Syk Tech Llc | Apparatur til topisk anvendelse af kvældstofoxid samt fremgangsmåder |
CN108524570A (zh) * | 2018-06-28 | 2018-09-14 | 遵义医学院 | 一种具有促进皮肤溃疡创面修复的复方艾纳香生肌凝胶剂及其制备方法 |
-
2020
- 2020-06-02 EP EP20732654.7A patent/EP3980032A1/en active Pending
- 2020-06-02 CA CA3142109A patent/CA3142109A1/en active Pending
- 2020-06-02 AU AU2020286987A patent/AU2020286987A1/en active Pending
- 2020-06-02 BR BR112021023632A patent/BR112021023632A2/pt unknown
- 2020-06-02 GB GB2118474.2A patent/GB2599818B/en active Active
- 2020-06-02 CN CN202080052446.2A patent/CN114126629B/zh active Active
- 2020-06-02 WO PCT/GB2020/051329 patent/WO2020245574A1/en active Search and Examination
- 2020-06-02 US US17/616,485 patent/US20220257642A1/en active Pending
- 2020-06-02 JP JP2021572283A patent/JP2023510662A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020286987A1 (en) | 2021-12-16 |
WO2020245574A1 (en) | 2020-12-10 |
CN114126629A (zh) | 2022-03-01 |
CA3142109A1 (en) | 2020-12-10 |
CN114126629B (zh) | 2024-08-30 |
EP3980032A1 (en) | 2022-04-13 |
GB2599818B (en) | 2024-01-31 |
GB2599818A (en) | 2022-04-13 |
JP2023510662A (ja) | 2023-03-15 |
US20220257642A1 (en) | 2022-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021023632A2 (pt) | Métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratório | |
BR112021023832A8 (pt) | Métodos e composições para geração de óxido nítrico e usos dos mesmos | |
PH12019502725A1 (en) | Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety | |
MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
BR112018005454A2 (pt) | administração de potencializadores de cftr deuterados | |
BR112015016466A2 (pt) | método para o tratamento de câncer baseado no estado de mutação de k-ras | |
BR112014009528A8 (pt) | métodos e composições para tratar eritropoiese ineficaz | |
BR112012024349A2 (pt) | métodos de tratamento de carcinoma hepatocelular | |
BR112015023520A2 (pt) | purificação do conjugado de anticorpo-fármaco (adc) | |
BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
BR112017015773A2 (pt) | muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo | |
BR112013020620A2 (pt) | análogos de ácido 4-hidroxibutírico | |
MX2019003397A (es) | Metodos para tratar trastornos mitocondriales y metabolicos. | |
BR112014009790A2 (pt) | composto para modulação antisense da expressão de gccr, seu uso e composição | |
BR112015008847A2 (pt) | composições compreendendo ácido peróxido | |
BR112017018328A2 (pt) | anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo | |
BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
BR112018072339A2 (pt) | tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados | |
BR112022021454A2 (pt) | Óxido nítrico ou composições liberadoras de óxido nítrico para uso no tratamento de sars-cov e sars-cov-2 | |
BRPI1003162A8 (pt) | Composições para tratamento da sensibilidade dental | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BRPI0903359B8 (pt) | composição farmacêutica de metformina, ácido acetilsalicílico e composto de serotonina para o tratamento do câncer | |
BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
BR112022008544A2 (pt) | Composições e métodos e usos relacionados às mesmas | |
BR112022024120A2 (pt) | Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo |